8 studies found for:    sotatercept | Celgene [Lead]
Show Display Options
Rank Status Study
1 Active, not recruiting Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Conditions: Anemia;   Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Low to Intermediate-1 MDS
Intervention: Drug: Sotatercept
2 Terminated Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Conditions: Anemia;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small-Cell Lung;   Bladder Cancer;   Cancer of Head and Neck;   Uterine Cervical Cancer
Interventions: Drug: ACE-011 - 15 mg;   Drug: ACE-011 - 30 mg;   Drug: ACE-011 - 45 mg
3 Active, not recruiting Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
Conditions: Beta Thalassemia Major;   Beta Thalassemia Intermedia
Interventions: Drug: Sotatercept 0.1mg/kg;   Drug: Sotatercept 0.3mg/kg;   Drug: Sotatercept 0.5mg/kg;   Drug: Sotatercept 0.75mg/kg;   Drug: Sotatercept 1.0mg/kg;   Drug: Sotatercept 1.5mg/kg
4 Completed A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Condition: Anemia
Interventions: Biological: Sotatercept;   Biological: Placebo
5 Active, not recruiting A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis
Conditions: Anemia;   Kidney Failure, Chronic
Intervention: Biological: Sotatercept
6 Terminated Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Condition: Solid Tumors
Intervention: Drug: ACE 011
7 Terminated Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Condition: Chemotherapy Induced Anemia
Interventions: Biological: Biological: ACE-011;   Drug: Placebo
8 Completed A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: ACE-011;   Biological: Placebo

Indicates status has not been verified in more than two years